1. Which of the following is true about changes to the MIPS program reporting for 2020?

2. Landmark comparative clinical trials for diabetic macular edema and wet age-related macular degeneration include the following trials:

3. You receive a denial for your authorization to use an on-label drug after a patient has failed bevacizumab treatment. Which of the following are reasonable strategies to undertake?

4. Which of the following is NOT true with regard to comparison of aflibercept to ranibizumab to bevacizumab?

« Return to Activity